Clinical Trials
13 trialsNCT07495579 2026-05-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT07379047 2026-04-24
GISTAR-1
Ningbo Newbay Technology Development Co., Ltd
Phase 2/3 Not yet recruiting
NCT07514429 2026-04-07
RELEVANT-HCC
Asan Medical Center
Phase 2 Not yet recruiting
NCT07514455 2026-04-07
RECOMEND
Asan Medical Center
Phase 2 Not yet recruiting
NCT07483684 2026-03-19
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT07392866 2026-02-09
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 2/3 Not yet recruiting
NCT07384377 2026-02-03
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT06283134 2026-01-07
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
Phase 1 Not yet recruiting
NCT07134205 2025-08-21
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT07115550 2025-08-11
A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma
Huai'an First People's Hospital
Phase NA Not yet recruiting
NCT07078305 2025-07-22
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06946849 2025-04-27
SED-RO-ICC
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06682611 2024-11-12
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase 1/2 Not yet recruiting